title: Sustainability of National Immunization Programme (NIP) performance and financing following Global Alliance for Vaccines and Immunization (GAVI) support to the Democratic Republic of the Congo (DRC).
abstract: BACKGROUND
  The Global Alliance for Vaccines and Immunization (GAVI) is a public-private global health partnership aiming to increase access to immunisation in poor countries. The Democratic Republic of the Congo (DRC) is the third largest recipient of GAVI funds in terms of cumulative disbursed support. We provided a comprehensive assessment of GAVI support and analysed trends in immunisation performance and financing in the DRC from 2002 to 2010.
  
  
  METHODS
  The scope of the analysis includes GAVI's total financial support and the value of vaccines and syringes purchased by GAVI for the DRC from 2002 to 2010. Data were collected through a review of published and grey literature and interviews with key stakeholders in the DRC. We assessed the allocation and use of GAVI funds for each of GAVI's support areas, as well as trends in immunisation performance and financing.
  
  
  RESULTS
  DTP3 coverage increased from 2002 (38%) to 2007 (72%) but had decreased to a level below 70% in 2008 (68%) and 2010 (63%). The overall funding for vaccines increased from US$5.4 million in 2006 to US$30.5 million in 2010 (mostly from GAVI support for new vaccines). However, during the same period, the funding from national (government) and international (GAVI and other donors) sources for routine immunisation services (except vaccines) decreased from US$36.4 million to US$24.4 million. This drop in overall funding (33%) primarily affected surveillance, transport, and cold chain equipment.
  
  
  CONCLUSIONS
  GAVI support to DRC has enhanced significant progress in routine immunisation performance and financing during 2002-2010. Although progress has been partly sustained, the initial observed increase in DTP3 coverage and available funding for routine immunisation halted towards the end of the analysis period, coinciding with tetravalent and pentavalent vaccine introduction. These findings highlight the need for additional efforts to ensure the sustainability of routine immunization program performance and financing.
authors: Agence de Médecine Préventive, Paris, France. jblegargasson@aamp.org
authors: Jean-Bernard
authors: JB
authors: Le Gargasson
authors: J Gabrielle
authors: JG
authors: Breugelmans
authors: Benoît
authors: B
authors: Mibulumukini
authors: Alfred
authors: A
authors: Da Silva
authors: Anaïs
authors: A
authors: Colombini
mesh_terms: D003299:Cooperative Behavior; D015023:Democratic Republic of the Congo; D014943:Global Health / Q000191:economics / Q000639:trends; D006801:Humans; D007114:Immunization / Q000191:economics* / Q000639:trends; D017589:Immunization Programs / Q000191:economics* / Q000639:trends*; D007391:International Cooperation; D055818:Public-Private Sector Partnerships / Q000191:economics; D014612:Vaccines / Q000191:economics*
chemical_list: D014612:Vaccines